Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weaker-than-expected quarterly financial results.
Earnings and Revenue Miss Expectations Regenxbio reported a first-quarter loss of $1.72 per share, wider than analyst expectations of a $1.34 loss per share
Revenue totaled $6.39 million, well below the consensus estimate of $25.8 million. The company’s revenue declined 93% year-on-year from $89.0 million in the first quarter of 2025. Regenxbio said the drop was largely due to a $70 million upfront license payment from Nippon Shinyaku recognized in the prior-year period, as well as a $12.2 million reduction in ZOLGENSMA royalty revenue after certain licensed U.S. patents expired in January 2026.
Duchenne Trial Meets Primary Endpoint Investor sentiment improved after the company announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial evaluating RGX-202. According to Regenxbio, the study achieved its primary endpoint with high statistical significance. The company said 93% of patients reached RGX-202 microdystrophin expression levels above 10%, with a reported p-value of less than 0.0001.